The steadfast advance of the synthetic biology field has enabled scientists to use genetically
engineered cells, instead of small molecules or biologics, as the basis for the development …

Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumours
despite the use of multi-agent conventional chemotherapy regimens. Such poor outcomes …

Recent advances in targeted therapy and immunotherapy have once again raised the hope
that a cure might be within reach for many cancer types. Yet, most late-stage cancers are …

More than 60 years ago, the effect whereby radiotherapy at one site may lead to regression
of metastatic cancer at distant sites that are not irradiated was described and called the …

The past decade of cancer research has been marked by a growing appreciation of the role
of immunity in cancer. Mutations in the tumour genome can cause tumours to express …

Our ability to generate bacterial strains with unique and increasingly complex functions has
rapidly expanded in recent times. The capacity for DNA synthesis is increasing and costing …

Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020.
The survival rates for patients with other gastrointestinal malignancies have increased …

Purpose GVAX pancreas, granulocyte-macrophage colony-stimulating factor–secreting
allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including …

Chimeric antigen receptors (CAR) are synthetic receptors that target T cells to cell-surface
antigens and augment T-cell function and persistence. Mesothelin is a cell-surface antigen …

Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional
treatments, although a limited number of early-stage patients can undergo radical resection …